Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer.
Adam LaffertyAlice C O'FarrellGiorgia MigliardiNiraj KhemkaAndreas U LindnerFrancesco SassiEugenia R ZanellaManuela SalvucciEvy VanderheydenElodie ModaveBram BoeckxLuise HalangJohannes BetgeMatthias P A EbertPatrick DickerGuillem ArgilésJosep TaberneroRodrigo DienstmannEnzo MedicoDiether LambrechtsAndrea BertottiClaudio IsellaLivio TrusolinoJochen H M PrehnAnthony L ByrnePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Subtype classification systems represent canonical "termini a quo" (starting points) to support REG biomarker identification, and provide a platform to identify resistance mechanisms and novel contexts of vulnerability. Incorporating functional characterization of biological systems may optimize the biomarker identification process for multitargeted kinase inhibitors.